Phase I dose-escalation study of milademetan in patients with relapsed or refractory acute myeloid leukemia

Long-term survival in patients with acute myeloid leukemia (AML) remains low, and current treatment modalities are inadequate. Milademetan (DS-3032, RAIN-32), a small-molecule specific murine double minute 2 inhibitor, has shown a p53 status-dependent antitumor effect in vitro studies. This is the f...

Descripción completa

Detalles Bibliográficos
Autores principales: Sekiguchi, Naohiro, Kasahara, Senji, Miyamoto, Toshihiro, Kiguchi, Toru, Ohno, Hitoshi, Takagi, Taiga, Tachibana, Masaya, Sumi, Hiroyuki, Kakurai, Yasuyuki, Yamashita, Tomonari, Usuki, Kensuke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Nature Singapore 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9813109/
https://www.ncbi.nlm.nih.gov/pubmed/36258088
http://dx.doi.org/10.1007/s12185-022-03464-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9813109/
https://www.ncbi.nlm.nih.gov/pubmed/36258088
http://dx.doi.org/10.1007/s12185-022-03464-z

Ejemplares similares